CN101007841A - Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor - Google Patents
Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor Download PDFInfo
- Publication number
- CN101007841A CN101007841A CN 200710066953 CN200710066953A CN101007841A CN 101007841 A CN101007841 A CN 101007841A CN 200710066953 CN200710066953 CN 200710066953 CN 200710066953 A CN200710066953 A CN 200710066953A CN 101007841 A CN101007841 A CN 101007841A
- Authority
- CN
- China
- Prior art keywords
- ace
- rice
- sephadex
- lyophilized powder
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 54
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 49
- 235000009566 rice Nutrition 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000005764 inhibitory process Effects 0.000 title description 2
- 240000007594 Oryza sativa Species 0.000 title 1
- 241000209094 Oryza Species 0.000 claims abstract description 48
- 229920005654 Sephadex Polymers 0.000 claims abstract description 35
- 239000012507 Sephadex™ Substances 0.000 claims abstract description 34
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 58
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 31
- 108010073032 Grain Proteins Proteins 0.000 abstract description 22
- 102000004169 proteins and genes Human genes 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 235000013339 cereals Nutrition 0.000 abstract description 15
- 230000002255 enzymatic effect Effects 0.000 abstract description 13
- 238000004007 reversed phase HPLC Methods 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 56
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 56
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 56
- 239000003531 protein hydrolysate Substances 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 15
- 238000011160 research Methods 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 7
- 230000007071 enzymatic hydrolysis Effects 0.000 description 6
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 1
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种从米糟中分离、纯化ACE抑制活性肽的方法,以酶解后的米糟蛋白酶解物为原料,包括以下步骤:1)采用葡聚糖凝胶Sephadex G-15对米糟蛋白酶解物进行分离制备,得分离组分;然后对所得的每种分离组分分别进行ACE抑制活性的测定;2)将上述ACE抑制活性测定值最高的分离组分真空冷冻干燥后制成冻干粉,再将上述冻干粉溶解于蒸馏水中配成浓度为5mg冻干粉/mL的溶液,然后对上述溶液采用反相高效液相色谱法进行分离分析,所获色谱峰值最大的即为纯化后的ACE抑制活性肽。根据本发明方法制得的ACE抑制活性肽,分子量为645.3,其氨基酸一级结构为Phe-Asn-Gly-Phe-Tyr。本发明方法具有设备简单、工艺简洁、重复性好的优点,能够被广泛采用。
The invention discloses a method for separating and purifying ACE-inhibiting active peptides from rice grains. The enzymolyzed rice grains protein enzymolyzate is used as a raw material, comprising the following steps: 1) Sephadex G-15 is used to The enzymatic hydrolyzate of rice grain protein is separated and prepared to obtain isolated components; then the ACE inhibitory activity of each of the obtained isolated components is measured respectively; into lyophilized powder, then the above-mentioned lyophilized powder is dissolved in distilled water to form a solution with a concentration of 5 mg lyophilized powder/mL, and then the above-mentioned solution is separated and analyzed by reversed-phase high performance liquid chromatography, and the obtained chromatographic peak is the largest It is the purified ACE inhibitory active peptide. The ACE-inhibiting active peptide prepared by the method of the invention has a molecular weight of 645.3, and its amino acid primary structure is Phe-Asn-Gly-Phe-Tyr. The method of the invention has the advantages of simple equipment, simple process and good repeatability, and can be widely used.
Description
技术领域technical field
本发明属于生物工程和蛋白质化学领域,涉及一种从米糟中分离、纯化ACE抑制活性肽的方法,以及该方法所制得的ACE抑制活性肽。The invention belongs to the fields of bioengineering and protein chemistry, and relates to a method for separating and purifying ACE-inhibiting active peptides from rice grains, and the ACE-inhibiting active peptides prepared by the method.
背景技术Background technique
随着人们生活水平的提高和自我保护意识及安全意识的增强,通过非药物疗法既能达到治病的目的、又可避免合成药剂对人体的损伤,因此已被越来越多的人所接受。高血压病是一种常见的多发病,全球患高血压人数已经超过5亿;同时高血压病又是冠心病、心脏及肾脏功能衰竭的最主要因素,因此治疗高血压成为全球医学界面临的艰巨任务。目前国内外正式用于临床的血管紧张素抑制剂有16种以上,正在研究中的有80种。尽管酶解法获得的血管紧张素转换酶(ACE)抑制活性肽没有化学合成的疗效显著;但其无毒副作用,安全性高,对血压正常者没有副作用。目前,日本是研究ACE抑制活性肽最多的国家,主要是从乳源性蛋白质中提取,其次就是鱼类蛋白,其中一部分产品实现了工业化生产。而我国在这方面研究处于起步阶段,我国地大物博,有丰富的蛋白质资源及食品加工过程中产生的副产物,如何有效的把这些资源利用是今后的研究方向。With the improvement of people's living standards and the enhancement of self-protection awareness and safety awareness, non-drug therapy can not only achieve the purpose of curing diseases, but also avoid the damage of synthetic drugs to the human body, so it has been accepted by more and more people. . Hypertension is a common and frequently-occurring disease. The number of people suffering from hypertension worldwide has exceeded 500 million. At the same time, hypertension is the most important factor in coronary heart disease, heart and kidney failure. Therefore, the treatment of hypertension has become a challenge faced by the global medical community. daunting task. At present, there are more than 16 kinds of angiotensin inhibitors officially used clinically at home and abroad, and 80 kinds are under research. Although the angiotensin-converting enzyme (ACE) inhibitory active peptide obtained by enzymatic hydrolysis is not as effective as the chemically synthesized peptide, it has no toxic side effects, high safety, and no side effects on normotensive persons. At present, Japan is the country that studies the most ACE inhibitory active peptides, which are mainly extracted from milk-derived proteins, followed by fish proteins, some of which have been industrialized. However, the research in this area in our country is in its infancy. Our country has a vast land and abundant resources, and there are abundant protein resources and by-products produced in the process of food processing. How to effectively use these resources is the direction of future research.
肽类常用分离提取方法有膜分离技术、凝胶柱层析技术、离子交换层析、凝胶电泳、高效液相色谱、毛细管电泳等。由于食物蛋白质经过蛋白酶水解后产生的ACE抑制活性肽分子量一般都在1500以下,因此可以用过滤或活性炭吸附出去高分子量蛋白质和未水解的蛋白质,用超滤法除去不溶底物、分子量较大的蛋白质和肽类,就可以获得分子量较小的短肽。凝胶柱层析技术是根据分子的大小,通过多孔凝胶床而分离出不同分子量的多肽。该技术肽的回收率高,活性不被破坏、设备简单重复性好、是广泛被采用的技术。川岛用ODS树脂分离提取了较高活性的ACE抑制肽混合物后,再用SP Sephadex C-25进行离子交换层析,获得了很好的结果;河村幸雄用Sephadex G-25两种凝胶和Sephadex G-10,从大豆蛋白胃蛋白酶水解液分离到了较高活性的ACE抑制活性组分后,再经两次高效液相色谱分离获得了高纯度的ACE抑制活性肽。Astanwan等用Sephadex G-25凝胶层析和SP Sephadex C-25离子交换层析处理印度尼西亚干鱼酶解产物,获得了高ACE抑制活性短肽。Peptides commonly used separation and extraction methods include membrane separation technology, gel column chromatography technology, ion exchange chromatography, gel electrophoresis, high performance liquid chromatography, capillary electrophoresis, etc. Since the molecular weight of the ACE-inhibiting active peptide produced after the food protein is hydrolyzed by protease is generally below 1500, high molecular weight protein and unhydrolyzed protein can be removed by filtration or activated carbon, and insoluble substrate and larger molecular weight can be removed by ultrafiltration. For proteins and peptides, short peptides with smaller molecular weights can be obtained. Gel column chromatography separates polypeptides of different molecular weights through a porous gel bed according to the size of the molecules. This technology has a high recovery rate of peptides, no damage to the activity, simple equipment and good repeatability, and is a widely used technology. Kawashima used ODS resin to separate and extract the highly active ACE inhibitory peptide mixture, and then used SP Sephadex C-25 for ion exchange chromatography, and obtained good results; Kawamura Yukio used two gels of Sephadex G-25 and Sephadex G-10, after separating the high-activity ACE-inhibiting active components from soybean protein pepsin hydrolyzate, and then separated by high-performance liquid chromatography twice to obtain high-purity ACE-inhibiting active peptides. Astanwan et al. used Sephadex G-25 gel chromatography and SP Sephadex C-25 ion exchange chromatography to treat Indonesian dried fish enzymatic hydrolyzate, and obtained short peptides with high ACE inhibitory activity.
有关ACE抑制活性与结构关系的研究认为,ACE抑制活性与结构氨基酸序列中的C末端和N-末端氨基酸的性质有重要的关系。Cheung等认为,C末端氨基酸残基为芳香族氨基酸(Thr、Tyr、Phe)和脯氨酸时ACE抑制活性较高;此外,N-端氨基酸残基为疏水性的Val、Leu、Ile或碱性氨基酸时肽的抑制活性较高。日本学者报道玉米醇溶蛋白经酶解获得一种ACE抑制肽,其一级结构式为Leu-Pro-Pro。Kunio Suetsuna从大蒜中分离出7种二肽,其肽序列分别为Ser-Tyr、Gly-Tyr、Phe-Tyr、Asn-Tyr、Ser-Phe、Gly-Phe和Asn-Phe,将这些肽以不同剂量合成后以200mg/kg体重饲喂高血压大鼠发现有明显降血压作用。Toshiro等用胃肠道酶对蜂王浆蛋白水解、纯化所获得11种ACE抑制活性肽中,大部分肽的C末端氨基酸残基为Phe、Tyr,这也与Cheung等的观点一致。Studies on the relationship between ACE inhibitory activity and structure suggest that ACE inhibitory activity has an important relationship with the properties of the C-terminal and N-terminal amino acids in the structural amino acid sequence. Cheung et al. believed that the ACE inhibitory activity was higher when the C-terminal amino acid residues were aromatic amino acids (Thr, Tyr, Phe) and proline; in addition, the N-terminal amino acid residues were hydrophobic Val, Leu, Ile or alkali The inhibitory activity of the peptide was higher when the sex amino acid was used. Japanese scholars reported that an ACE inhibitory peptide was obtained by enzymatic hydrolysis of zein, and its primary structural formula was Leu-Pro-Pro. Kunio Suetsuna isolated seven dipeptides from garlic, and their peptide sequences were Ser-Tyr, Gly-Tyr, Phe-Tyr, Asn-Tyr, Ser-Phe, Gly-Phe and Asn-Phe, and these peptides were separated in different After dose synthesis, feeding hypertensive rats with 200mg/kg body weight found that it has obvious blood pressure lowering effect. Among the 11 ACE-inhibiting active peptides obtained by Toshiro et al. using gastrointestinal enzymes to hydrolyze and purify royal jelly, the C-terminal amino acid residues of most peptides are Phe and Tyr, which is also consistent with Cheung et al.
上述的研究结果说明,ACE抑制活性与氨基酸序列中的C末端和N-末端氨基酸的性质有重要关系,但也有一些ACE抑制活性较强的肽不符合上述情况。如Matsui等用碱性蛋白酶酶解沙丁鱼获得的ACE抑制活性肽主要由酸性氨基酸组成,疏水性氨基酸含量很低。The above research results indicate that the ACE inhibitory activity has an important relationship with the properties of the C-terminal and N-terminal amino acids in the amino acid sequence, but there are also some peptides with strong ACE inhibitory activity that do not meet the above conditions. For example, Matsui et al. used alkaline protease to hydrolyze sardines to obtain ACE inhibitory active peptides, which were mainly composed of acidic amino acids, and the content of hydrophobic amino acids was very low.
发明内容Contents of the invention
本发明要解决的技术问题是提供一种能快速分离、纯化米糟酶解后的ACE抑制活性肽的方法,以及依照该方法所得的活性肽。The technical problem to be solved by the present invention is to provide a method for rapidly separating and purifying the ACE-inhibiting active peptide after enzymatic hydrolysis of rice grains, and the active peptide obtained according to the method.
为了解决上述技术问题,本发明提供一种从米糟中分离、纯化ACE抑制活性肽的方法,以酶解后的米糟蛋白酶解物为原料,其特征是依次包括以下步骤:In order to solve the above-mentioned technical problems, the present invention provides a method for separating and purifying ACE-inhibiting active peptides from rice grains, using enzymatic hydrolyzed rice grain protein hydrolyzate as raw material, which is characterized in that it includes the following steps in sequence:
1)、采用葡聚糖凝胶Sephadex G-15对米糟蛋白酶解物进行分离制备,得分离组分;分离条件如下:1) Sephadex G-15 was used to separate and prepare rice grain protein hydrolyzate to obtain separated components; the separation conditions were as follows:
层析柱:长160cm、直径30mm,Chromatographic column: length 160cm, diameter 30mm,
填充物:葡聚糖凝胶G-15,Filling: Sephadex G-15,
流速:0.5-5mL/min,Flow rate: 0.5-5mL/min,
检测波长:280nm,Detection wavelength: 280nm,
洗脱液:蒸馏水,Eluent: distilled water,
上样量:25-50mL;Sample volume: 25-50mL;
然后对所得的每种分离组分分别进行ACE抑制活性的测定;Then carry out the mensuration of ACE inhibitory activity to each isolated fraction of gained;
2)、将上述ACE抑制活性测定值最高的分离组分真空冷冻干燥后制成冻干粉,再将上述冻干粉溶解于蒸馏水中配成浓度为5mg冻干粉/mL的溶液,然后对上述溶液采用反相高效液相色谱法进行分离分析,色谱分析条件如下:2), vacuum freeze-dry the isolated component with the highest measured value of the above-mentioned ACE inhibitory activity to make a lyophilized powder, then dissolve the above-mentioned lyophilized powder in distilled water to form a solution with a concentration of 5 mg lyophilized powder/mL, and then Above-mentioned solution adopts reverse-phase high-performance liquid chromatography to carry out separation and analysis, and chromatographic analysis condition is as follows:
色谱柱:C18P/N84176,长300mm、直径7.8mm;Chromatographic column: C18P/N84176, length 300mm, diameter 7.8mm;
流动相:按照45/55/0.1的体积比将乙腈、水和三氟乙酸混合后形成流动相;Mobile phase: Acetonitrile, water and trifluoroacetic acid are mixed according to the volume ratio of 45/55/0.1 to form the mobile phase;
检测:UV280nm;Detection: UV280nm;
流速:0.5-1mL/min;Flow rate: 0.5-1mL/min;
柱温:30℃;Column temperature: 30°C;
所获色谱峰值最大的即为纯化后的ACE抑制活性肽。The obtained chromatographic peak with the largest value is the purified ACE inhibitory active peptide.
本发明还提供了根据上述方法制得的ACE抑制活性肽,其分子量为645.3,其氨基酸一级结构为Phe-Asn-Gly-Phe-Tyr,命名为FNGFY。The present invention also provides the ACE-inhibiting active peptide prepared according to the above method, its molecular weight is 645.3, its amino acid primary structure is Phe-Asn-Gly-Phe-Tyr, named as FNGFY.
因为具有ACE抑制活性的一般都是分子量小于1000的小肽,因此,在本发明中,选用葡聚糖凝胶Sephadex G-15对米糟蛋白酶解物进行了分离。葡聚糖凝胶Sephadex G-15一般用于分离分子量小于1500的小肽,因此,比较适合分离米蛋糟白水解物中的ACE抑制肽。Because those with ACE inhibitory activity are generally small peptides with a molecular weight less than 1000, therefore, in the present invention, Sephadex G-15 was selected to separate the rice grain protein hydrolyzate. Sephadex G-15 is generally used to separate small peptides with a molecular weight less than 1500, so it is more suitable for separating ACE inhibitory peptides in rice protein gluten hydrolyzate.
在发明过程中,发明人应用反相高效液相色谱对ACE抑制活性肽Sephadex G-15分离组分F-II、F-III、F-IV、F-V、F-VI进行了分析,并利用反相高效液相色谱方法制备组分F-V中的F-V-IV,进一步采用质谱方法确定其分子量和氨基酸一级结构,结果显示,该组分含有分子量为645.3的为FNGFY(Phe-Asn-Gly-Phe-Tyr)的五肽。本发明首次运用反相高效液相色谱、质谱等方法从米糟蛋白酶解物中获得了具有较高ACE抑制活性的五肽,在国内外,有关此方面的研究尚未见报道。In the course of the invention, the inventors used reverse-phase high-performance liquid chromatography to analyze the separated components F-II, F-III, F-IV, F-V, and F-VI of the ACE inhibitory active peptide Sephadex G-15, and used reverse F-V-IV in component F-V was prepared by phase-high performance liquid chromatography, and its molecular weight and amino acid primary structure were determined by mass spectrometry. The results showed that this component contained FNGFY (Phe-Asn-Gly-Phe -Tyr) pentapeptide. The present invention for the first time obtains a pentapeptide with high ACE inhibitory activity from rice grain protein hydrolyzate by using reversed-phase high-performance liquid chromatography, mass spectrometry and other methods. At home and abroad, no research on this aspect has been reported.
本发明专利选用米糟蛋白作为研究原料,将通过酶解方法获得的酶解物进行分离、纯化获得血管紧张素转换酶(ACE)抑制活性肽,并进行一级结构的确定和鉴定。既能促进米糟资源的综合利用,又能寻找开发出具有特定生理功能的生物活性肽,为开发和合成利用新型生物活性肽奠定基础。The patent of the present invention selects rice waste protein as the research raw material, separates and purifies the enzymatic hydrolyzate obtained by enzymatic hydrolysis to obtain angiotensin-converting enzyme (ACE) inhibitory active peptide, and determines and identifies the primary structure. It can not only promote the comprehensive utilization of rice grain resources, but also find and develop bioactive peptides with specific physiological functions, laying a foundation for the development, synthesis and utilization of new bioactive peptides.
本发明是采用凝胶柱过滤法结合高效液相色谱、质谱技术对酶解物进行快速分离、纯化,并确定其初级结构。本发明采用的方法简洁、成本低,获得的ACE抑制活性肽没有太大损害,抑制活性高。现有报道中并没有关于米糟酶解法生产ACE抑制活性肽的报道,更没有这种ACE抑制活性肽的结构发明。与目前已经报道的其他食品类蛋白源ACE抑制活性肽相比,本发明主要优点体现在所采用的原料价格低廉且米糟蛋白是一种优质的蛋白源、原料中蛋白质含量高、生产出来的产品感官优等。The invention uses a gel column filtration method combined with high performance liquid chromatography and mass spectrometry to quickly separate and purify the enzymatic hydrolyzate and determine its primary structure. The method adopted in the present invention is simple and low in cost, and the obtained ACE inhibitory active peptide does not have too much damage and has high inhibitory activity. In the existing reports, there is no report on the production of ACE-inhibiting active peptides by enzymatic hydrolysis of rice grains, let alone the invention of the structure of such ACE-inhibiting active peptides. Compared with the ACE-inhibiting active peptides of other food protein sources that have been reported so far, the main advantages of the present invention are that the raw materials used are low in price, rice grain protein is a high-quality protein source, the protein content in the raw materials is high, and the produced The sensory quality of the product is excellent.
大米蛋白作为优良营养品质蛋白,不仅氨基酸组成非常合理,而且由于其不含类似致敏因子,具有低过敏性特点,无异味、消化率高等优点。目前还未见米糟中酶解分离纯化出具有ACE抑制活性的小肽。采用本发明方法制备的肽回收率高,活性不被破坏。本发明的方法具有设备简单、工艺简洁、重复性好的优点,能够被广泛采用。As a high-quality nutritional protein, rice protein not only has a very reasonable amino acid composition, but also has the characteristics of hypoallergenicity, no peculiar smell, and high digestibility because it does not contain similar allergens. So far, no small peptides with ACE inhibitory activity have been isolated and purified by enzymatic hydrolysis from rice grains. The recovery rate of the peptide prepared by the method of the invention is high, and the activity is not destroyed. The method of the invention has the advantages of simple equipment, simple process and good repeatability, and can be widely used.
附图说明Description of drawings
下面结合附图对本发明的具体实施方式作进一步详细说明。The specific implementation manners of the present invention will be described in further detail below in conjunction with the accompanying drawings.
图1是米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离图谱;Fig. 1 is the separation pattern of rice grain protein enzymatic hydrolyzate Sephadex G-15 Sephadex G-15;
图2是米糟蛋白酶解物Sephadex G-15分离组分的IC50(mg/mL)对比图;Fig. 2 is the IC 50 (mg/mL) comparison chart of rice grain protein hydrolyzate Sephadex G-15 separation fraction;
图3是米糟蛋白酶解物Sephadex G-15分离组分F-V的反相高效液相色谱分析图;Fig. 3 is the reversed-phase high-performance liquid chromatographic analysis figure of rice grain protein hydrolyzate Sephadex G-15 separation component F-V;
图4是米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离F-V-IV组分制备图。Fig. 4 is a diagram showing the preparation of F-V-IV fractions separated by Sephadex G-15 from rice waste protein enzymatic hydrolyzate.
具体实施方式Detailed ways
米糟蛋白酶解物的制备:生产方法见本申请人前一个发明专利所述(申请号:200610050845.7,申请时间:2006年5月)。Preparation of rice waste protein hydrolyzate: the production method is described in the applicant's previous invention patent (application number: 200610050845.7, application time: May 2006).
实施例1:采用葡聚糖凝胶Sephadex G-15对米糟蛋白酶解物进行分离制备,得分离组分:Example 1: Sephadex G-15 was used to separate and prepare rice grain protein hydrolyzate, and the separated components were obtained:
在分离过程中,本发明选用160cm(长)×30mm层析柱,检测波长为280nm,洗脱液为蒸馏水。洗脱液流速为0.5ml/min,上样量为25-30ml,根据核酸蛋白检测仪器中的波长数值OD280变化进行样品的收集。按照上述给定的操作条件,能收集获得具有ACE抑制活性的短肽。In the separation process, the present invention selects a chromatographic column of 160 cm (length) × 30 mm, the detection wavelength is 280 nm, and the eluent is distilled water. The flow rate of the eluent is 0.5ml/min, the sample volume is 25-30ml, and the sample is collected according to the change of the wavelength value OD 280 in the nucleic acid protein detection instrument. According to the above given operating conditions, short peptides with ACE inhibitory activity can be collected and obtained.
从图1中可以看出,米糟蛋白酶解物经葡聚糖凝胶Sephadex G-15分离后,分成比较明显的六个多肽组分,分别命名为F-I、F-II、F-III、F-IV、F-V、F-VI。葡聚糖凝胶SephadexG-15分离出的组分F-I、F-II、F-III、F-IV、F-V、F-VI所占的峰面积分别为36.08%、45.93%、7.98%、2.13%、3.03%、4.85%。其中F-I和F-II所占比重较高,分别为36.08%和46.93%。米糟蛋白酶解物经葡聚糖凝胶Sephadex G-15分离后的蛋白质回收率达到了84.9%。It can be seen from Figure 1 that after the hydrolyzate of rice grain protein is separated by Sephadex G-15, it is divided into six relatively obvious polypeptide components, which are named F-I, F-II, F-III, and F-III respectively. -IV, F-V, F-VI. The peak areas of the fractions F-I, F-II, F-III, F-IV, F-V, and F-VI separated by Sephadex G-15 were 36.08%, 45.93%, 7.98%, and 2.13%, respectively , 3.03%, 4.85%. Among them, F-I and F-II accounted for a relatively high proportion, 36.08% and 46.93% respectively. The protein recovery rate of rice waste protein hydrolyzate separated by Sephadex G-15 reached 84.9%.
在本研究中,为进一步研究米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离组分的ACE抑制活性,对分离所得的F-I、F-II、F-III、F-IV、F-V、F-VI六个组分进行了ACE抑制活性的测定,同时还测定了六个组分的蛋白质含量,具体结果见表1。In this study, in order to further study the ACE inhibitory activity of Sephadex G-15 separation fraction of rice waste protein enzymatic hydrolyzate, F-I, F-II, F-III, F-IV, F-V, The six components of F-VI were tested for their ACE inhibitory activity, and the protein content of the six components was also measured. The specific results are shown in Table 1.
ACE抑制活性的测定用反相高效液相色谱法(RP-HPLC)进行测定,该方法目前已经得到认可和应用。The determination of ACE inhibitory activity is carried out by reversed-phase high-performance liquid chromatography (RP-HPLC), which has been recognized and applied at present.
表1米糟蛋白酶解物各个分离组分的蛋白含量及ACE抑制活性Table 1 Protein content and ACE inhibitory activity of each fraction of rice grain protein hydrolyzate
从上表1中可以看出,米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离所得各组分F-I、F-II、F-III、F-IV、F-V、F-VI均具有ACE抑制活性,其ACE抑制活性分别为23.7%、47.5%、74.6%、68.4%、84.7%、77.9%,其中F-III、F-IV、F-V、F-VI的ACE抑制活性较高。It can be seen from the above table 1 that the components F-I, F-II, F-III, F-IV, F-V, and F-VI obtained by separating the enzymatic hydrolyzate of rice grain protein from Sephadex G-15 all have ACE Inhibitory activity, its ACE inhibitory activities were 23.7%, 47.5%, 74.6%, 68.4%, 84.7%, 77.9%, respectively, and the ACE inhibitory activities of F-III, F-IV, F-V, and F-VI were higher.
实施例2:米糟蛋白酶解物Sephadex G-15分离组分的ACE抑制活性的半抑制浓度(IC50)研究及其比较:Embodiment 2: the half-inhibitory concentration (IC50) research and comparison of the ACE inhibitory activity of rice grain protein hydrolyzate Sephadex G-15 separation fraction:
原料:分别采用实施例1所述方法获得米糟蛋白酶解物的凝胶分离组分作为研究原料。Raw materials: The gel-separated fractions of rice grain protein enzymatic hydrolyzate obtained by the method described in Example 1 were used as research raw materials.
为准确描述组分F-I、F-II、F-III、F-IV、F-V、F-VI的ACE抑制活性,分别测定了各个组分的ACE抑制活性的半抑制浓度(IC50)。测定结果如图2所示。由图2可得知,分离组分F-I、F-II、F-III、F-IV、F-V、F-VI的ACE抑制活性的半抑制浓度(IC50)分别为0.502g/mL、0.171mg/mL、0.041mg/mL、0.019mg/mL、0.011mg/mL、0.017mg/mL。这些数据表明F-III、F-IV、F-V、F-VI的ACE抑制活性较高;其中,ACE抑制活性最高的组分为F-V,其ACE抑制活性的半抑制浓度(IC50)为0.011mg/mL。研究结果提示组分F-V中可能含有ACE抑制活性较高的组分。In order to accurately describe the ACE inhibitory activity of the components FI, F-II, F-III, F-IV, FV, and F-VI, the half-inhibitory concentration (IC 50 ) of the ACE inhibitory activity of each component was determined respectively. The measurement results are shown in FIG. 2 . It can be known from Figure 2 that the half-inhibitory concentrations (IC 50 ) of the ACE inhibitory activity of the isolated fractions FI, F-II, F-III, F-IV, FV, and F-VI were 0.502 g/mL and 0.171 mg, respectively. /mL, 0.041mg/mL, 0.019mg/mL, 0.011mg/mL, 0.017mg/mL. These data show that F-III, F-IV, FV, and F-VI have higher ACE inhibitory activity; among them, the component with the highest ACE inhibitory activity is FV, and the half-inhibitory concentration (IC 50 ) of its ACE inhibitory activity is 0.011mg /mL. The results of the study suggested that the component FV may contain components with higher ACE inhibitory activity.
表2中列举了部分不同食物来源的ACE抑制活性抑制物质的半抑制浓度(IC50),并与米糟蛋白酶解物进行了比较。从表2中可见,米糟蛋白酶解物的ACE抑制活性相当于从日本清酒中获得的多肽IYPNM,而米糟蛋白酶解物经葡聚糖凝胶Sephadex G-15分离所得各组分F-I、F-II、F-III、F-IV、F-V、F-VI的ACE抑制活性均明显高于鸡蛋蛋白酶解物,其中,F-III、F-IV、F-V、F-VI的ACE抑制活性高于螃蟹、丁香鱼、丁香鱼来源的蛋白酶解物。Table 2 lists the half-inhibitory concentrations (IC 50 ) of ACE inhibitory substances from different food sources, and compares them with rice grain protein hydrolyzate. It can be seen from Table 2 that the ACE inhibitory activity of the rice grain protein hydrolyzate is equivalent to the polypeptide IYPNM obtained from Japanese sake, and the rice grain protein hydrolyzate was separated by Sephadex G-15. -II, F-III, F-IV, FV, and F-VI had significantly higher ACE inhibitory activities than egg protein hydrolysates, and among them, F-III, F-IV, FV, and F-VI had higher ACE inhibitory activities than Protein hydrolyzate derived from crab, clove fish, clove fish.
表2部分不同食物来源的ACE抑制活性抑制物质的半抑制浓度(IC50)Table 2 The half-inhibitory concentration (IC 50 ) of the ACE inhibitory activity inhibitors from different food sources
实施例3:米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离F-V组分的色谱分离与反相高效液相色谱制备:Example 3: Chromatographic separation and reversed-phase high-performance liquid chromatography preparation of rice grain protein enzymatic hydrolyzate Sephadex G-15 to separate F-V components:
为进一步探明具有高血管紧张素转换酶(ACE)抑制活性的组分F-V,采用反相高效液相色谱法对F-V进行分离分析,具体如下:In order to further prove the component F-V with high angiotensin-converting enzyme (ACE) inhibitory activity, adopt reversed-phase high-performance liquid chromatography to carry out separation and analysis to F-V, specifically as follows:
在本实施中,将蛋白酶解物葡聚糖凝胶Sephadex G-15分离组分F-V真空冷冻干燥后制成冻干粉,冷冻干燥的工艺条件为:温度-45℃、真空度20Pa。In this implementation, the proteolyzed dextran gel Sephadex G-15 separation fraction F-V was vacuum freeze-dried to make a freeze-dried powder. The freeze-drying process conditions were: temperature -45°C, vacuum degree 20Pa.
再将上述冻干粉溶解于蒸馏水中配成浓度为5mg冻干粉/mL的溶液,用C18反相高效液相色谱进行了分离分析。其色谱条件如下:Then the above lyophilized powder was dissolved in distilled water to form a solution with a concentration of 5 mg lyophilized powder/mL, which was separated and analyzed by C18 reverse-phase high performance liquid chromatography. Its chromatographic conditions are as follows:
色谱柱:C18P/N84176(300mm×7.8mm)Chromatographic column: C18P/N84176 (300mm×7.8mm)
流动相:乙腈/水/三氟乙酸,45/55/0.1(V/V)Mobile phase: acetonitrile/water/trifluoroacetic acid, 45/55/0.1(V/V)
检测:UV280nmDetection: UV280nm
流速:0.5mL/minFlow rate: 0.5mL/min
柱温:30℃。Column temperature: 30°C.
研究按照上述方法所获得六个色谱峰(见图3),其中F-V-IV的活性最大,用反相高效液相色谱对F-V-IV进行了制备。其色谱条件如下:According to the six chromatographic peaks obtained by the above method (see Figure 3), the activity of F-V-IV is the largest, and F-V-IV was prepared by reversed-phase high performance liquid chromatography. Its chromatographic conditions are as follows:
色谱柱:YWG-C18(300mm×7.8mm)Chromatographic column: YWG-C18 (300mm×7.8mm)
流动相:A:0.1%TFA/水;B:0.1%TFA/ACNMobile phase: A: 0.1% TFA/water; B: 0.1% TFA/ACN
检测:UV220nmDetection: UV220nm
流速:1.0mL/minFlow rate: 1.0mL/min
柱温:30℃Column temperature: 30°C
经反复收集图3所示部分后进行冷冻干燥,保存进行下一步的质谱分析。The parts shown in Figure 3 were collected repeatedly, then freeze-dried, and stored for the next step of mass spectrometry analysis.
实施例4 :米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离组分F-V-IV质谱分析:Example 4: Mass spectrometry analysis of F-V-IV fractions separated by Sephadex G-15 of Sephadex G-15 enzymatic hydrolyzate of rice grain protein:
质谱在蛋白质的一级结构确定中发挥重要作用。为确定米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离组分F-V-IV的中多肽的氨基酸顺序,测定了多肽的LC MS.M质谱。对米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离组分F-V-IV进行液相-质谱分析。用Bruker DataAnalysis 3.0软件进行了分析,组分F-V-IV的质谱图中可以明显看出一个分子量为645.3的组分。Mass spectrometry plays an important role in the determination of the primary structure of proteins. In order to determine the amino acid sequence of the polypeptide in fractions F-V-IV of Sephadex G-15 Sephadex G-15 separation fraction of rice grain protein hydrolyzate, the LC MS.M mass spectrum of the polypeptide was determined. Liquid chromatography-mass spectrometry analysis of Sephadex G-15 fractions F-V-IV of rice waste protein enzymatic hydrolyzate. Analyzed with Bruker DataAnalysis 3.0 software, a component with a molecular weight of 645.3 can be clearly seen in the mass spectrum of component F-V-IV.
对米糟蛋白酶解物葡聚糖凝胶Sephadex G-15分离组分F-V-IV中一个分子量为645.3的组分进行二级质谱(MS/MS)分析。根据质谱分析中的简单断裂规则,肽类可产生氨基酸质量碎片及某个或某几个氨基酸残基+CO+NH、残基+CO、残基+NH、残基-NH、残基-CO或残基-CO-NH的质量碎片。将这些质量碎片与氨基酸进行比对就可以得知原来的肽中的氨基酸序列。经过氨基酸比对结果表明,分子量为645.3的肽的氨基酸一级结构为FNGFY(Phe-Asn-Gly-Phe-Tyr)。A fraction with a molecular weight of 645.3 in Sephadex G-15 Sephadex G-15 separation fraction F-V-IV was analyzed by MS/MS by MS/MS. According to the simple fragmentation rules in mass spectrometry, peptides can produce amino acid mass fragments and one or several amino acid residues + CO + NH, residue + CO, residue + NH, residue -NH, residue - CO or mass fragments of the residue -CO-NH. By comparing these mass fragments with amino acids, the amino acid sequence in the original peptide can be known. The results of amino acid alignment showed that the primary amino acid structure of the peptide with a molecular weight of 645.3 was FNGFY (Phe-Asn-Gly-Phe-Tyr).
最后,还需要注意的是,以上列举的仅是本发明的若干个具体实施例。显然,本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。Finally, it should be noted that the above examples are only some specific embodiments of the present invention. Obviously, the present invention is not limited to the above embodiments, and many variations are possible. All deformations that can be directly derived or associated by those skilled in the art from the content disclosed in the present invention should be considered as the protection scope of the present invention.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710066953 CN101007841A (en) | 2007-01-29 | 2007-01-29 | Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710066953 CN101007841A (en) | 2007-01-29 | 2007-01-29 | Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101007841A true CN101007841A (en) | 2007-08-01 |
Family
ID=38696532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710066953 Pending CN101007841A (en) | 2007-01-29 | 2007-01-29 | Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101007841A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103772484A (en) * | 2013-12-30 | 2014-05-07 | 浙江省农业科学院 | Dipeptide SD with dual functions of lowering blood pressure and blood fat and application thereof |
CN104342473A (en) * | 2013-08-06 | 2015-02-11 | 北京市农林科学院 | Preparation and purification method of amaranth seed antihypertensive bioactive peptide |
CN106520878A (en) * | 2016-11-25 | 2017-03-22 | 邵阳学院 | Method for preparing active peptide from waste fermented grains |
CN107988297A (en) * | 2017-11-27 | 2018-05-04 | 丸美化妆品株式会社 | The application of a kind of preparation method and vinasse small-molecular peptides of vinasse small-molecular peptides in skin care item |
CN110269129A (en) * | 2019-07-03 | 2019-09-24 | 南京黄教授食品科技有限公司 | A kind of duck source ACE inhibitor peptides and preparation method thereof |
CN111484545A (en) * | 2020-03-31 | 2020-08-04 | 华南农业大学 | Blood pressure-lowering oligopeptide derived from rice distiller's grains and its preparation method and application |
-
2007
- 2007-01-29 CN CN 200710066953 patent/CN101007841A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104342473A (en) * | 2013-08-06 | 2015-02-11 | 北京市农林科学院 | Preparation and purification method of amaranth seed antihypertensive bioactive peptide |
CN103772484A (en) * | 2013-12-30 | 2014-05-07 | 浙江省农业科学院 | Dipeptide SD with dual functions of lowering blood pressure and blood fat and application thereof |
CN106520878A (en) * | 2016-11-25 | 2017-03-22 | 邵阳学院 | Method for preparing active peptide from waste fermented grains |
CN107988297A (en) * | 2017-11-27 | 2018-05-04 | 丸美化妆品株式会社 | The application of a kind of preparation method and vinasse small-molecular peptides of vinasse small-molecular peptides in skin care item |
CN107988297B (en) * | 2017-11-27 | 2021-08-10 | 丸美化妆品株式会社 | Preparation method of vinasse small molecular peptide and application of vinasse small molecular peptide in skin care product |
CN110269129A (en) * | 2019-07-03 | 2019-09-24 | 南京黄教授食品科技有限公司 | A kind of duck source ACE inhibitor peptides and preparation method thereof |
CN111484545A (en) * | 2020-03-31 | 2020-08-04 | 华南农业大学 | Blood pressure-lowering oligopeptide derived from rice distiller's grains and its preparation method and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Angiotensin-I converting enzyme (ACE) inhibitory tripeptides from rice protein hydrolysate: Purification and characterization | |
Liu et al. | Purification and characterization of angiotensin I converting enzyme inhibitory peptides from jellyfish Rhopilema esculentum | |
CN104450839B (en) | The preparation method of the rice bran protein peptide with ACE inhibitory activity | |
CN110964087B (en) | Fugu active peptide and preparation method thereof | |
CN111072756B (en) | Tetrodotoxin ACE inhibitory peptide and preparation method thereof | |
Ma et al. | Antihypertensive activity of the ACE–renin inhibitory peptide derived from Moringa oleifera protein | |
CN101007841A (en) | Method for separating and purifying ACE inhibition peptide from rice draff and active peptide obtained therefor | |
CN111100186B (en) | Puffer fish polypeptide with ACE inhibitory activity and preparation method thereof | |
CN111647043A (en) | Oligopeptide with platelet resisting and antithrombotic functions containing Hyp-Gly sequence | |
CN112552394B (en) | Yak antihypertensive peptide and preparation method thereof | |
CN111004309B (en) | ACE inhibitory peptide prepared from Takifugu flavidus fish skin and preparation method thereof | |
CN111499691B (en) | ACE inhibitory peptide P1, application thereof and preparation method thereof | |
CN111518164B (en) | ACE inhibitory peptide P2, application thereof and preparation method thereof | |
CN115368440A (en) | Euphausia superba oligomeric composite peptide | |
Xiong et al. | Preparation, identification, and molecular docking of novel elastase inhibitory peptide from walnut (Juglans regia L.) meal | |
Baraiya et al. | Potential of fish bioactive peptides for the prevention of global pandemic non-communicable disease: production, purification, identification, and health benefits | |
CN104694604A (en) | Preparation method of hippocampus angiotensin-converting enzyme inhibitory peptide | |
CN110105431A (en) | A kind of sesame polypeptide and its extracting method and preparing the application in anti-oxidant and/or blood-pressure drug | |
CN106008669A (en) | Hazelnut ACE inhibitory peptides and preparation method of same | |
CN101830967A (en) | Oligopeptide with angiotensin transferase inhibiting activity and preparation method thereof | |
CN103275180B (en) | Navodon septentrionalos fish head protein antioxidant peptide as well as preparation method and application thereof | |
CN117820424A (en) | Angiotensin I converting enzyme inhibitory peptide and application thereof | |
CN113880916B (en) | Yak skin antioxidant polypeptide and preparation method and application thereof | |
CN106831947B (en) | A novel functional peptide derived from oyster and its use | |
JP4790325B2 (en) | Antihypertensive peptide derived from meat protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070801 |